Nuvelo and ARCA biopharma Advance Toward Completion... (uding theproposed brand name is currentl...)

Nuvelo and ARCA biopharma Advance Toward Completion of Merger

Date:12/1/2008

uding the proposed brand name, is currently under review by the U.S. Food and Drug Administration. The companion genetic test for Gencaro is in development by ARCA's partner, Laboratory Corporation of America. For more information please visit http://www.arcabiopharma.com.

Forward-looking statements

This press release contains "forward-looking statements" which include, without limitation, statements regarding the completion of the proposed merger transaction between Nuvelo, ARCA and Dawn Acquisition Sub, Inc., the transaction's anticipated timing, progress and anticipated completion of the combined company's clinical stage and research programs, which statements are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on the companies' managements' current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward- looking statements as a result of many factors, including, without limitation, failure of Nuvelo or ARCA's stockholders to approve the merger, the ability to complete the transaction contemplated by this communication in a timely fashion, the risk that Nuvelo's and ARCA's business operations will not be integrated successfully; the combined company's inability to further identify, develop and achieve commercial success for products and technologies; the risk that the combined company's financial resources will be insufficient to meet the combined company's business objectives; uncertainties relating to drug discovery and the regulatory approval process; clinical development processes; enrollment rates for patients in the companies' clinical trials; changes in relationships with strategic partners and dependence upon strategic partners for the perf
'/>"/>

SOURCE Nuvelo, Inc.; ARCA biopharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company
2. Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers
3. Nuvelo Reports Second Quarter 2008 Financial Results
4. Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008
5. Therapure Biopharma Inc. Announces Manufacturing Agreement with Biomedical Frontiers Incorporated -- Contract will Support Phase II Trials for Thalassemia Treatment
6. MySignatureBook Certified Compliant With SAFE-BioPharma Digital Standard(TM)
7. Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors
8. Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission
9. InCode BioPharmaceutics Appoints New President and CEO
10. Med Discovery and Laborium Biopharma Sign a Bioprocess Development Partnership Agreement
11. Frost & Sullivan Awards Baxters BioPharma Solutions Business the 2008 North American Customer Service Leadership of the Year Award

Post Your Comments:

Nuvelo and ARCA biopharma Advance Toward Completion...(uding theproposed brand name is currentl...)